As of 2024-12-15, the Relative Valuation of Egetis Therapeutics AB (publ) (EGTX.ST) is (24.08) SEK. This relative valuation is based on P/E multiples. With the latest stock price at 6.52 SEK, the upside of Egetis Therapeutics AB (publ) based on Relative Valuation is -469.3%.
The range of the Relative Valuation is (23.84) - (23.97) SEK.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 31.7x - 31.8x | 31.8x |
| Forward P/E multiples | 29.3x - 35.1x | 32.2x |
| Fair Price | (23.84) - (23.97) | (24.08) |
| Upside | -465.6% - -467.7% | -469.3% |
| Date | P/E |
| 2024-12-13 | -8.66 |
| 2024-12-12 | -8.75 |
| 2024-12-11 | -8.86 |
| 2024-12-10 | -8.87 |
| 2024-12-09 | -8.33 |
| 2024-12-06 | -8.29 |
| 2024-12-05 | -7.60 |
| 2024-12-04 | -7.52 |
| 2024-12-03 | -7.13 |
| 2024-12-02 | -7.46 |
| 2024-11-29 | -7.45 |
| 2024-11-28 | -7.17 |
| 2024-11-27 | -7.18 |
| 2024-11-26 | -7.44 |
| 2024-11-25 | -7.49 |
| 2024-11-22 | -7.09 |
| 2024-11-21 | -7.17 |
| 2024-11-20 | -7.21 |
| 2024-11-19 | -7.09 |
| 2024-11-18 | -6.92 |
| 2024-11-15 | -7.36 |
| 2024-11-14 | -7.34 |
| 2024-11-13 | -6.88 |
| 2024-11-12 | -7.17 |
| 2024-11-11 | -6.51 |
| 2024-11-08 | -6.31 |
| 2024-11-07 | -5.73 |
| 2024-11-06 | -5.45 |
| 2024-11-05 | -5.50 |
| 2024-11-04 | -5.54 |
| 2024-11-01 | -5.72 |
| 2024-10-31 | -5.85 |
| 2024-10-30 | -5.82 |
| 2024-10-29 | -5.90 |
| 2024-10-28 | -6.00 |
| 2024-10-25 | -6.05 |
| 2024-10-24 | -6.09 |
| 2024-10-23 | -6.21 |
| 2024-10-22 | -6.31 |
| 2024-10-21 | -6.18 |
| 2024-10-18 | -6.25 |
| 2024-10-17 | -6.46 |
| 2024-10-16 | -6.19 |
| 2024-10-15 | -6.05 |
| 2024-10-14 | -6.10 |
| 2024-10-11 | -6.14 |
| 2024-10-10 | -6.11 |
| 2024-10-09 | -5.74 |
| 2024-10-08 | -5.84 |
| 2024-10-07 | -5.75 |